Malaria continues to pose a significant global health threat, necessitating the development of effective vaccines to complement existing control measures. Recent advancements in our understanding of Plasmodium parasite biology have identified novel parasite ligands as promising vaccine antigens to target the complex life cycle of the parasite. These parasite ligands, expressed on the surface of Plasmodium parasites, play crucial roles in host cell invasion, immune evasion, and disease pathogenesis. By targeting these ligands, vaccines aim to induce immune responses capable of preventing parasite invasion, blocking transmission, or eliminating infected cells. This article explores the potential of selected novel parasite ligands, including Apical Membrane Antigen 1, Circumsporozoite Protein, Thrombospondin-Related Anonymous Protein and Rhoptry Neck Protein 2, as vaccine candidates against malaria. Recent research efforts have focused on optimizing vaccine formulations, enhancing immunogenicity, and evaluating vaccine efficacy in preclinical and clinical studies. These novel vaccine candidates offer promising prospects for malaria vaccine development, with the potential to contribute significantly to malaria control and elimination efforts. Continued research into the immunogenicity, efficacy, and safety of these vaccine candidates is essential for advancing malaria vaccine development and ultimately achieving the goal of malaria eradication.
HTML PDFShare this article
Malaria Control & Elimination received 1187 citations as per Google Scholar report
